Treatment with IL-2 and IL-12 inhibits tumour cell division in SL2 lymphoma

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2633-2642

  Masztalerz, Agnieszka ^a   Van Luyn, Marja ^c   Werner, Naomi ^c   Molema, Grietje ^c   Everse, Linda Ann ^b   Den Otter, Willem ^b,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Faculty of Veterinary Medicine   (Netherlands)

Author keywords

Immunotherapy; Interleukin 12; Interleukin 2

Indexed keywords

CD31 ANTIGEN; COLLAGEN TYPE 4; INTERLEUKIN 12; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOOD VESSELS; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; LEUKOCYTES; LYMPHOMA; MICE; MICE, INBRED DBA; MICROSCOPY, ELECTRON; NECROSIS; RNA, MESSENGER;

EID: 6444226744     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Maas RA, Dullens HFJ, De Jong WH and Den Otter W: Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose Interleukin-2. Cancer Res 49: 7037-7040, 1989.
2. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rutten VPMG and Ruitenberg EJ: Low doses of Interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 13: 2453-2456, 1993.
3. Rutten VPMG, De Jong WAC, Klein WR, Den Otter W, Steerenberg PA and Ruitenberg EJ: Immunotherapy of bovine ocular squamous cell carcinoma: isolation, culture and characterization of lymphocytes present in the tumor. Anticancer Res 11: 1259-1264, 1991.
4. Van Es RJJ, Baselmans AHC, Den Otter W, Van Dijk JE, Koole R and Den Otter W: Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic antitumor activity. Anticancer Res 20: 4163-4170, 2000.
5. Wigginton JM and Wiltrout RH: IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2: 513-520, 2002.
6. Lin JX and Leonard WJ: Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 8: 313-321, 1997.
7. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008-4016, 1994.
8. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD and Storkus WJ: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1709, 1994.
9. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1229, 1993.
10. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H and Okumura K: Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 29: 1390-1394, 1999.
11. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M and Taniguchi M: Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1628, 1997.
12. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K and Matsuno S: Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 60: 1111-1116, 2000.
13. Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES and Tosato G: Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96: 1900-1912, 2000.
14. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber JM, Liao F, Liu L and Tosato G: Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 64: 384-389, 1998.
15. Dias S, Boyd R and Balkwill F: IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 78: 361-367, 1998.
16. Gee MS, Koch CJ, Evans SM, Jenkins WT, Pletcher CH, Jr, Moore JS, Koblish HK, Lee J, Lord EM, Trinchieri G and Lee WM: Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 59: 4882-4885, 1999.
17. Myers KJ, Eppihimer MJ, Hall L and Wolitzky B: Interleukin-12-induced adhesion molecule expression in murine liver. Am J Pathol 152: 457-467, 1998.
18. Lentsch AB, Miller FN and Edwards MJ: Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother 47: 243-248 1999.
19. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG and Marincola FM: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3: 35-50, 2002.
20. Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Stricter RM, Ward J, Green JE and Wiltrout RH: Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166: 1156-1165, 2001.
21. Masztalerz A, Van Rooijen N, Den Otter W and Everse LA: Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother 52: 235-242, 2003.
22. Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC and Wiltrout RH: IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108: 51-62, 2001.
23. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM and Hamilton TA: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161: 927-933, 1998.